Jeil Pharmaceutical, 19.66% Increase Amid COVID-19 (Nafamostat) Theme Uptrend

On the 28th, the COVID-19 (Nafamostat) theme showed strength by rising 3.98% compared to the previous day, while Jeil Pharm, which is attracting attention as a related stock, surged 19.66% compared to the previous day. Jeil Pharm is known as a company spun off from Jeil Pharma Holdings.

[Graph] Major stock price changes in the COVID-19 (Nafamostat) theme

According to the analysis by Thinkpool Robo Algorithm RASSI, Jeil Pharm’s quant financial score was 13.16 points, ranking 8th in the quant financial ranking within the COVID-19 (Nafamostat) related theme. This can be interpreted as Jeil Pharm having relatively low investment attractiveness from a financial perspective. On the other hand, Chong Kun Dang Holdings ranked first in the quant financial ranking with higher growth, stability, and profitability scores compared to the average of other stocks.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of the Robo Algorithm’s analysis based on each company’s sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.